Recently, the U.S. Food and Drug Administration cleared a new noninvasive stereotactic radiotherapy system indicated for use in treating cancer in breast tissue. This new system will provide greater accuracy in delivering radiation therapy to breast tumours while saving surrounding breast tissue. Radiation therapy is a crucial treatment option for cancer patients. Approximately 60 percent of all cancer patients are generally treated with some form of radiation therapy.
Radiation therapy kills the tumour cells by damaging their DNA. Along with the tumour cells, it can also potentially damage healthy tissue around a tumour. The newly approved system is generally indicated for use in the noninvasive stereotactic delivery of a radiation dose to a portion (partial volume) of the breast in conjunction with breast-conserving treatment. This procedure will involve the delivery of radiation to…
